siRNA Downregulation of 11beta-HSD1 for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, primarily focused on lowering intraocular pressure (IOP), lack understanding of the pathophysiological mechanisms leading to neuronal damage, and existing therapies have limitations in effectively managing elevated IOP, necessitating a more targeted approach to address the underlying causes.
Innovation Solution
The use of small interfering RNA (siRNA) to downregulate the expression of 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1), which plays a crucial role in regulating sodium transport and aqueous humor secretion, thereby modulating intraocular pressure, is employed to treat glaucoma and other eye disorders characterized by altered IOP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If current medications or surgeries are used to lower intraocular pressure, then IOP can be reduced, but the pathophysiological mechanisms leading to neuronal damage remain unaddressed and therapy effectiveness is limited
Solution Approach 1:
The patent uses 11beta-HSD1 as an intermediary target - by inhibiting this enzyme with selective inhibitors, the pathway from cortisone to cortisol is blocked, thereby reducing glucocorticoid-mediated neuronal damage while also affecting IOP regulation. This intermediary approach addresses both pressure and underlying pathophysiology.
Solution Approach 2:
The patent changes the biochemical parameter of glucocorticoid concentration in the eye by inhibiting 11beta-HSD1 enzyme activity. This parameter change reduces the conversion of inactive cortisone to active cortisol, thereby protecting neurons from glucocorticoid toxicity while also modulating IOP.
2Stress or pressure
If conventional glaucoma therapies are applied, then some IOP reduction is achieved, but the treatments lack targeting of underlying pathophysiological causes
Solution Approach 1:
The patent applies local quality by using topically administered 11beta-HSD1 inhibitors that specifically target ocular tissues. The enzyme inhibitor acts locally in the eye to reduce glucocorticoid production in ocular tissues, providing targeted therapy that addresses both IOP and neuronal protection without systemic side effects.
3Adaptability or versatility
If RNAi technology is used to downregulate 11beta-HSD1 expression, then targeted gene silencing is achieved, but delivery and stability of siRNA molecules present challenges
Solution Approach 1:
The patent uses chemical modification of siRNA molecules as an intermediary solution - by adding protective chemical groups to the siRNA structure, stability against nucleases is improved and cellular uptake is enhanced, thereby facilitating delivery without requiring complex delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA-based approach effectively reduces intraocular pressure, as demonstrated by significant percentage decreases in normotensive rabbits, providing a targeted mechanism to address the underlying pathophysiology of glaucoma and other eye conditions.
Implementation Method 1
RNA interference refers to the process of sequence-specific post-transcriptional gene silencing mediated by short interfering RNAs (siRNA)
Implementation Method 2
11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1), activating cortisol from cortisone, and 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2), inactivating cortisol to cortisone
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).